Vijayakrishna K. Gadi, MD, PhD | Authors

Management of ILD in HER2+ BC

June 01, 2021

Expert panelists react to polling questions and give their input on the management both symptomatic and asymptomatic interstitial lung disease in HER2+ breast cancer, also touching on this impact in the era of COVID-19.